Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2702409 | 1.00 | ESR2 (0.42) | ESR2BRD4LMNAMAPK1HTT | |
| SCHEMBL13223460 | 1.00 | ESR2 (0.42) | ESR2BRD4LMNAMAPK1HTT | |
| SCHEMBL14555105 | 0.93 | ESR2 (0.38) | ESR2BRD4 | |
| SCHEMBL24197652 | 0.85 | ESR2 (0.50) | ESR2BRD4 | |
| SCHEMBL240852 | 0.85 | ESR2 (0.50) | ESR2BRD4 | |
| SCHEMBL5733 | 0.85 | — | — | |
| SCHEMBL7865334 | 0.84 | LMNA (0.38) | ESR2LMNAMAPK1HTTHRH1 | |
| SCHEMBL12454240 | 0.84 | — | — | |
| SCHEMBL17133476 | 0.84 | — | — | |
| SCHEMBL18090623 | 0.84 | LMNA (0.38) | ESR2LMNAMAPK1HTTHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682993-B2 | Anticancer compounds | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-06-20 | — | — | US | disclosed |
| US-9550741-B2 | Benzoisothiazole compounds and methods of treating schizophrenia | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2017-01-24 | — | — | US | disclosed |
| US-20160096811-A1 | BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS | SHANAGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2016-04-07 | — | — | US | disclosed |
| US-20160009728-A1 | ANTICANCER COMPOUNDS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096811-A1 | BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS | HTR3A, SLC6A3, HTR5A | ESR2 3179/4885BRD4 1053/4885LMNA 3956/4885 |
| US-20160009728-A1 | ANTICANCER COMPOUNDS | MKI67, TP53, BAX | ESR2 2730/4885BRD4 1391/4885LMNA 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.